Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study
2020 ◽
Vol 26
(1)
◽
pp. 154-162
2016 ◽
Vol 14
(5)
◽
pp. 457-464
◽
2016 ◽
Vol 14
(5)
◽
pp. 415-419
◽
2019 ◽
Vol 17
(3)
◽
pp. 150-159
2018 ◽
Vol 16
(5)
◽
pp. 365-368
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 4612-4612
◽
2011 ◽
Vol 29
(15_suppl)
◽
pp. e15114-e15114